Vaccinex Inc's Comment on Sales, Marketing and Customers
The company serves customers who bill federal programs for pharmaceutical products, including federal healthcare benefit programs and private third-party payors such as private insurers. Its activities include pharmaceutical companies' product and patient assistance programs, manufacturer reimbursement support services, specialty pharmacies, and grants to independent charitable foundations. In compliance with the federal Physician Payments Sunshine Act, manufacturers of drugs, devices, biologics, and medical supplies reimbursed under Medicare, Medicaid, or the Children’s Health Insurance Program report payments and transfers of value to healthcare providers, including physicians, physician assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists, and certified nurse-midwives. The markets served encompass federal healthcare programs, private insurers, and foreign governments where products are marketed and sold.
In a robust display of innovation, Vaccinex Inc. has recently provided exciting updates on its proprietary ActivMAb platform, a revolutionary technology central to the discovery of therapeutic antibodies. Capitalizing on this cutting-edge capability, the company has secured multiple project deals that underscore its significant impact in the field of cancer immunotherapy. Further amplifying these developments, Vaccinex is poised to present its promising findings at the Society for Immunotherapy of Cancer (SITC) Annual Meeting, scheduled for November 9, 2024.The ActivMAb platform represents a cornerstone of Vaccinex s research and development efforts. This unique technology leverages an innovative approach to...
Overview of Pepinemab and its Phase 1b/2 TrialVaccinex Inc. recently presented new findings from the SIGNAL-AD Phase 1b/2 clinical trial of its investigational therapeutic agent, Pepinemab, at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference held in Madrid, Spain. The trial primarily investigates the potential of Pepinemab in treating Mild Cognitive Impairment (MCI) and Mild Dementia associated with Alzheimer’s disease. New Biomarker and Cognitive Effects ReportedDuring the presentation at the conference, Vaccinex outlined promising results related to new biomarkers, which are critical for measuring disease progression and treatment efficacy. These biomarkers suggest an enhanced understandi...
Understanding the Promise of Pepinemab: A Novel Approach for Alzheimer s Disease The quest for viable treatments for Alzheimer s disease (AD) remains one of the most formidable challenges in the field of neuroscience. Vaccinex Inc., a clinical-stage biotechnology company known for its innovative therapeutics, has recently reported promising data from its SIGNAL-AD Phase 1b/2 clinical trial of Pepinemab in Alzheimer s Disease. This development marks a critical step forward in the fight against a condition that affects millions worldwide. Interpreting the SIGNAL-AD Trial Results The SIGNAL-AD trial is designed to evaluate the safety, tolerability, and effectiveness of Pepinemab in patients with Alzheimer s dis...
Vaccinex Inc’s Comment on Sales, Marketing and Customers
The company serves customers who bill federal programs for pharmaceutical products, including federal healthcare benefit programs and private third-party payors such as private insurers. Its activities include pharmaceutical companies' product and patient assistance programs, manufacturer reimbursement support services, specialty pharmacies, and grants to independent charitable foundations. In compliance with the federal Physician Payments Sunshine Act, manufacturers of drugs, devices, biologics, and medical supplies reimbursed under Medicare, Medicaid, or the Children’s Health Insurance Program report payments and transfers of value to healthcare providers, including physicians, physician assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists, and certified nurse-midwives. The markets served encompass federal healthcare programs, private insurers, and foreign governments where products are marketed and sold.
Sources:
Vaccinex Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Vaccinex Inc’s corporate clients.
For your research, we’ve provided 9 tables on Vaccinex Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
